Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone

Fineline Cube Dec 29, 2025
Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Fineline Cube Dec 29, 2025
Company Deals

Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics

Fineline Cube Dec 29, 2025
Company Deals

Hybio Pharmaceutical, Dr. Reddy’s Forge Peptide API Partnership

Fineline Cube Dec 29, 2025
Company Deals

Shionogi Acquires RADICAVA ALS Business for $2.5 Billion from Tanabe Pharma

Fineline Cube Dec 23, 2025
Company Policy / Regulatory

NDRC Expands Foreign Investment in Healthcare with 2025 Catalogue

Fineline Cube Dec 29, 2025
Company Drug

Sino Biopharmaceutical’s TQH3906 Achieves 90% PASI 75 Response in Phase 2 Psoriasis Trial

Fineline Cube Dec 29, 2025
Company Drug

AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy

Fineline Cube Dec 29, 2025
Company Drug

CSPC SYH2056 FDA Approval Targets Depression with 5-HT2A Agonist

Fineline Cube Dec 4, 2025

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2056 tablets, a Category 1 chemical drug, has...

Company Drug

Antengene XPOVIO sNDA Hong-Kong Approval Expands MM DLBCL Indications

Fineline Cube Dec 4, 2025

Antengene Corporation Limited (HKG: 6996) announced that Hong Kong’s Department of Health approved two supplementary...

Company Drug

Duality DB-1324 ADC FDA IND Approval Advances GSK Partnership

Fineline Cube Dec 4, 2025

Duality Biotherapeutics, Inc. (HKG: 9606) announced that its Investigational New Drug (IND) application for DB-1324,...

Policy / Regulatory

NHSA Guangzhou Drug-List Conference Releases 2025 Medical Insurance Formulary

Fineline Cube Dec 4, 2025

The National Healthcare Security Administration (NHSA) announced it will host the 2025 Innovative Drugs High-Quality...

Company Deals

Simcere deuremidevir RSV Licensing Deal Targets China Breakthrough

Fineline Cube Dec 4, 2025

Simcere Pharmaceutical Group Limited (HKG: 2096) and Vigonvita Life Sciences Co., Ltd. (HKG: 2630) entered...

Company Deals

Henlius Fovinaciclib CDK4-6 Breast-Cancer China Commercialization

Fineline Cube Dec 4, 2025

Henlius Biotech (HKG: 2696) announced a collaboration with Avanc Pharmaceutical Co., Ltd. to advance the...

Company Drug

Hengrui Remimazolam ICU Sedation NMPA Application Accepted

Fineline Cube Dec 3, 2025

Jiangsu Hengrui Pharmaceutical Co., Ltd (SHA: 600276, HKG: 1276) announced that China’s National Medical Products...

Others

Novo Nordisk CagriSema Pediatric Obesity Trial to Enroll 460 Children

Fineline Cube Dec 3, 2025

Novo Nordisk (NYSE: NVO) is planning to test its experimental obesity drug CagriSema in overweight...

Company Drug

Antengene ATG-022 CLDN18.2 ADC Gets China Nod for Keytruda Combo in Gastric Cancer

Fineline Cube Dec 3, 2025

Antengene Corporation Limited (HKG: 6996) announced that China’s National Medical Products Administration (NMPA) has approved...

Company Drug

MSD MK-2214 Fast Track Alzheimer Data Positive

Fineline Cube Dec 3, 2025

Merck Sharp & Dohme Inc. (MSD, NYSE: MRK) released first‑in‑human data for MK-2214 and MK-1167 in...

Policy / Regulatory

China Drug-Price Registration System Launches with First Batch of 10 Products

Fineline Cube Dec 3, 2025

China’s Drug Price Registration System officially launched today with the first batch of 10 drug...

Company Deals

3SBio HK$3.1B Placement Funds R&D Pipeline for 705, 706, 008

Fineline Cube Dec 3, 2025

3SBio Inc. (HKG: 1530) conditionally agreed to place 105,169,500 shares at HK$29.62 per share, raising...

Company Drug

Generate GB-0895 Asthma Phase III Trials to Enroll 1,600 Patients

Fineline Cube Dec 3, 2025

Generate: Biomedicines today announced plans to initiate two global Phase III clinical trials (SOLAIRIA-1 and...

Company Drug

Henlius HLX14 Denosumab Biosimilar NDA Accepted by China CDE

Fineline Cube Dec 3, 2025

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that the National Medical Products Administration’s Center for...

Company Deals

New-Radiomedicine Series-D Raises 800M Yuan for Radiopharmaceuticals

Fineline Cube Dec 3, 2025

Chengdu New Radiomedicine Technology Co., Ltd. announced completion of its Series D financing round, raising...

Company Deals Drug

Kura ziftomenib Sale Triggers $135M Kyowa-Kirin Payment

Fineline Cube Dec 3, 2025

Kura Oncology, Inc. (NASDAQ: KURA) announced completion of the first US commercial sale of KOMZIFTI...

Company Medical Device

Roche cobas-liat Whooping-Cough Test Secures FDA Clearance

Fineline Cube Dec 3, 2025

Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its cobas liat system-based point‑of‑care test for whooping...

Company Drug

Henlius HLX37 Bispecific NMPA Approval Targets Advanced Solid Tumors

Fineline Cube Dec 2, 2025

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that its self-developed investigational new drug, HLX37 (Recombinant...

Company Drug

Leads-Biolabs LBL047 Bispecific Secures China IND Approval for SLE

Fineline Cube Dec 2, 2025

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that the National Medical Products Administration (NMPA)...

Company Deals

Shanghai Bao Pharma IPO HKEX Raises HK$1 Billion for Biotech Pipeline

Fineline Cube Dec 2, 2025

Shanghai Bao Pharmaceuticals Co., Ltd. (HKG: 2659) successfully listed on the Hong Kong Stock Exchange...

Posts pagination

1 … 8 9 10 … 602

Recent updates

  • Jenscare Scientific Submits CE Mark Application for JensClip TMVr System in EU
  • TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone
  • Sino Biopharmaceutical’s TQH3906 Achieves 90% PASI 75 Response in Phase 2 Psoriasis Trial
  • HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology
  • Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Jenscare Scientific Submits CE Mark Application for JensClip TMVr System in EU

Company Deals

TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone

Company Drug

Sino Biopharmaceutical’s TQH3906 Achieves 90% PASI 75 Response in Phase 2 Psoriasis Trial

Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.